ASX Announcement

Medibio Limited - 17 May 2017



Demand for Medibio's corporate wellness technology results in second commercial agreement with Australian Corporate Wellness provider

Sydney, Australia – 17 May 2017: Medibio Limited (MEB or the Company) is pleased to announce that Medibio and Vital Conversations have entered into a second commercial agreement to launch Australia's Biggest Mental Health Check-in. In the Check-in, Vital Conversations has combined their comprehensive online assessment of mental health with Medibio's objective mental wellness diagnostics. The partnership is focussed on reducing the \$11B annual cost to Australian workplaces.

Australia's Biggest Mental Health Check-in aims to deliver a large scale corporate wellness initiative utilising wearable technology and online psychological health software. The Check-in will be launched commercially to large corporate customers that have a pool of more than 45,000 employees across Australia and internationally. This is a four-fold increase in volume on the 2016 Check-in, making it the world's largest scale corporate wellness initiative utilising wearable technology and online psychological health software.

"We are very excited about participating for the second time in this program because it validates our technology's ability to serve an increasing mental health population in a commercial setting," said Jack Cosentino, CEO of Medibio.

In addition to providing assessment of current mental illness, the Check-in measures a number of variables that can proactively reduce or prevent poor mental health from developing. Organisations such as Broadspectrum, PwC, St John of God Health Care are among those investing in the program to measure key indexes of workforce wellbeing. The Medibio and Vital Conversations offering combines to give each participant a private, proactive program downloaded directly to their own device.

"Wellness has been criticised for lacking clear metrics, and for failing to combine actual baseline data with targeted, more efficient outcomes. It is time we used digital technology to make it easier to assess and change mental health" said Creator of the Check-in and Managing Director of Vital Conversations, Peta Slocombe. "Medibio's technology epitomises the driving force behind the Check-in – which is that mental health can, and should be, measured to maximise the effectiveness of interventions. This partnership challenges the stigma that mental health is not as real as physical health," she went on to say.

To learn more about Vital Conversations visit <u>www.vitalconversations.com.au</u> or <u>www.mentalhealthcheckin.com</u>

To learn more about Medibio visit www.Medibio.com.au

– ENDS –

	Jack Cose
	CEO and N
	jack.coser
\bigcirc	T: + 1 612
	About Me
615	Medibio (
(UD)	diagnosis
20	over 15 y
$\bigcirc \bigcirc $	circadian
	assist in c
	by Johns
	trials will
	approach
(D)	method f
	stress/we listed on t
	iisteu on t
	About Vit
	Vital Conv
20	models th
$\bigcirc \bigcirc \bigcirc \bigcirc$	including
	Services a
65	Legal, En
	contracts
\bigcirc	
(
(\bigcirc)	

Further Information:	Website: www.medibio.com.au
Medibio Shareholder Enquiries to:	Medibio Media Enquiries to:
Jack Cosentino	Peter Taylor
CEO and Managing Director Medibio Limited	NWR Communications
jack.cosentino@medibio.com.au	peter@nwrcommunications.com.au
T: + 1 612 314 7201	T: +61 (0)412 036 231

About Medibio Limited

Medibio (ASX: MEB), is a medical technology company that has developed an objective test to assist in the diagnosis of depression, chronic stress and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilizes patented (and patent pending) circadian heart rate variability and cloud based proprietary algorithms delivering a quantifiable measure to assist in clinical diagnosis. Medibio's depression diagnostic is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa, among others. The clinical trials will support Medibio's application to become the first FDA approved, objective, and evidence based approach to the diagnosis of mental health disorders. Medibio's technology also provides an objective method for the assessment of stress and mental wellbeing that can be translated to the workplace stress/wellbeing market, wearable technology and App market. Located in Melbourne (Vic) Medibio is listed on the Australian Securities Exchange Ltd.

About Vital Conversations

Vital Conversations are leaders in the provision of psychological services, with innovative service delivery models that are changing the way psychological wellbeing is approached. They have a diverse client base including clients in private, public and not for profit sectors. Specialist areas include Executive Psychological Services and Preventative Mental Health. This encompasses a broad range of industries, including Health, Legal, Engineering, Property, Immigration, Child Protection, Social Services, and includes consultancy contracts with some of the largest corporates in Australia.